Stem definition | Drug id | CAS RN |
---|---|---|
antivirals neuraminidase inhibitors | 4823 | 330600-85-6 |
Dose | Unit | Route |
---|---|---|
0.60 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
fu (Fraction unbound in plasma) | 1 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
CL (Clearance) | 1.46 mL/min/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Date | Agency | Company | Orphan |
---|---|---|---|
April 13, 2018 | EMA | BIOCRYST UK LIMITED | |
Dec. 19, 2014 | FDA | BIOCRYST |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J05AH03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Neuraminidase inhibitors |
FDA MoA | N0000175436 | Neuraminidase Inhibitors |
FDA EPC | N0000175524 | Neuraminidase Inhibitor |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:52425 | acetylneuraminidase inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Influenza | indication | 6142004 | DOID:8469 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.6 | acidic |
pKa2 | 12.05 | acidic |
pKa3 | 13.73 | acidic |
pKa4 | 10.07 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 10391075 | Feb. 12, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER |
200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 10391075 | Feb. 12, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER |
200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS |
200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER |
200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sialidase 2 | Enzyme | Ki | 4.25 | CHEMBL | |||||
Neuraminidase | Enzyme | INHIBITOR | IC50 | 8.85 | CHEMBL | DRUG LABEL | |||
Neuraminidase | Enzyme | INHIBITOR | IC50 | 8.30 | CHEMBL | DRUG LABEL | |||
Neuraminidase | Enzyme | INHIBITOR | Ki | 9.08 | CHEMBL | DRUG LABEL | |||
Neuraminidase | Enzyme | IC50 | 9.40 | CHEMBL | |||||
Neuraminidase | Enzyme | IC50 | 10.15 | CHEMBL | |||||
Neuraminidase | Enzyme | IC50 | 8.70 | CHEMBL | |||||
Neuraminidase | Enzyme | IC50 | 7.03 | CHEMBL | |||||
Sialidase | Enzyme | IC50 | 4.40 | CHEMBL | |||||
Neuraminidase | Enzyme | IC50 | 9.52 | CHEMBL |
ID | Source |
---|---|
D03829 | KEGG_DRUG |
1041434-82-5 | SECONDARY_CAS_RN |
4034033 | VANDF |
CHEBI:85196 | CHEBI |
BCZ | PDB_CHEM_ID |
CHEMBL3989402 | ChEMBL_ID |
CHEMBL139367 | ChEMBL_ID |
C414210 | MESH_SUPPLEMENTAL_RECORD_UI |
DB06614 | DRUGBANK_ID |
1598078 | RXNORM |
231961 | MMSL |
30814 | MMSL |
d08335 | MMSL |
013296 | NDDF |
716121006 | SNOMEDCT_US |
763542005 | SNOMEDCT_US |
C1675326 | UMLSCUI |
154234 | PUBCHEM_CID |
QW7Y7ZR15U | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61364-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 27 sections |
Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72769-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 31 sections |
Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72769-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 31 sections |